Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
News headline image
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
News headline image
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
New 483 Observations Unlikely to Impact Much Awaited Revance's Daxi Approval, Says This Analyst ↗
 
Via Benzinga
News headline image
Revance Therapeutics: Q2 Earnings Insights ↗
  Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders. 
Via Benzinga
News headline image
AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022 ↗
Apple (AAPL) stock is a hot topic on Thursday following the tech giant's latest event showing off new products and we've got the details! 
Via InvestorPlace
News headline image
Why Is Revance Therapeutics (RVNC) Stock Soaring Today? ↗
RVNC stock is jumping 12% after the FDA approved its alternative to AbbVie's Botox. Revance's injection is supposed to last longer than Botox. 
Via InvestorPlace
News headline image
Recap: Revance Therapeutics Q1 Earnings ↗
Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines ↗
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ: RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of... 
Via Benzinga
News headline image
Why Asana Is Trading Higher By 24%; Here Are 24 Stocks Moving Premarket ↗
Gainers Asana, Inc. (NYSE: ASAN) rose 24.1% to $23.62 in pre-market trading after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. 
Via Benzinga
News headline image
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
From Revance Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 9, 2022 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
News headline image
Revance Therapeutics: Earnings Outlook ↗
  Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
News headline image
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Revance Therapeutics, Inc.
Via Business Wire
News headline image
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
From Revance Therapeutics, Inc.
Via Business Wire
News headline image
Revance Therapeutics's Return On Capital Employed Insights ↗
Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter. 
Via Benzinga
News headline image
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
From Revance Therapeutics, Inc.
Via Business Wire
News headline image
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
From Revance Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 10, 2022 ↗
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
News headline image
NASDAQ: RVNC Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Revance Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 04/27/2022 -- An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares over possible breaches of fiduciary duty by... 
Via SBWire
News headline image
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines ↗
Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for... 
Via Benzinga
News headline image
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.